Catheter ablation is superior to antiarrhythmic drugs in preventing arrhythmia recurrences and delaying AF progression in symptomatic, AAD-naïve patients with recurrent paroxysmal AF.
Does catheter ablation prevent arrhythmia recurrences and improve symptoms compared to antiarrhythmic drugs in symptomatic, AAD-naïve patients with recurrent paroxysmal AF?
The 2024 EHRA/HRS/APHRS/LAHRS consensus document establishes catheter ablation as the preferred first-line rhythm control therapy over AADs for symptomatic, AAD-naïve patients with recurrent paroxysmal AF.
The 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society consensus statement on catheter and surgical ablation of atrial fibrillation (AF) summarizes recent clinical trial data and technological advancements in AF ablation.1 It also provides updated clinical guidance for managing patients undergoing AF ablation. The following decalogue outlines the key changes included in this joint document (Figure 1). ... Randomized controlled clinical trials (RCTs) have documented that catheter ablation is superior to antiarrhythmic drugs (AADs) in preventing arrhythmia recurrences, improving patients’ symptoms and delaying AF progression to more advanced forms in symptomatic, AAD-naïve patients with recurrent paroxysmal AF, with a similar risk of adverse events. Therefore, catheter ablation should be preferred over AADs as first-line rhythm control therapy in this patient category.
“Ablation is the most effective way to prevent recurrences of atrial fibrillation and delay progression to more advanced forms. Pioneering techniques have emerged since the previous consensus in 2017, requiring new advice on who should receive this procedure and how to perform it in the safest and most effective manner.”
Tzeis et al. (Fri,) conducted a review in Atrial fibrillation. Catheter ablation vs. Antiarrhythmic drugs (AADs) was evaluated. Catheter ablation is superior to antiarrhythmic drugs in preventing arrhythmia recurrences and delaying AF progression in symptomatic, AAD-naïve patients with recurrent paroxysmal AF.